Predicted to enable several functions, including bis(5'-nucleosyl)-tetraphosphatase (asymmetrical) activity; glycine-tRNA ligase activity; and identical protein binding activity. Predicted to be involved in diadenosine tetraphosphate biosynthetic process and mitochondrial glycyl-tRNA aminoacylation. Predicted to act upstream of or within glycyl-tRNA aminoacylation. Predicted to be located in several cellular components, including axon; extracellular exosome; and secretory granule. Predicted to be active in mitochondrion. Human ortholog(s) of this gene implicated in Charcot-Marie-Tooth disease type 2D and distal hereditary motor neuronopathy type 5A. Orthologous to human GARS1 (glycyl-tRNA synthetase 1); PARTICIPATES IN dihydropyrimidine dehydrogenase deficiency pathway; dimethylglycine dehydrogenase deficiency pathway; nonketotic hyperglycinemia pathway; INTERACTS WITH 3-chloropropane-1,2-diol; allethrin; bisphenol A.
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of GARS1 protein
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of GARS1 protein
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of GARS1 protein
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GARS1 mRNA
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of GARS1 protein
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GARS1 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GARS1 mRNA